Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AXA1125
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AXA1125 has demonstrated an ability to reverse mitochondrial dysfunction and improve energetic efficiency via increased fatty acid oxidation, restored cellular homeostasis, and reduced inflammation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2023
Lead Product(s) : AXA1125
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AXA1125 has demonstrated an ability to reverse mitochondrial dysfunction and improve energetic efficiency via increased fatty acid oxidation, restored cellular homeostasis, and reduced inflammation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2022
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Subjects with NASH experienced clinically and statistically significant improvements in alanine aminotransferase (ALT), a measure of liver cell inflammation, at both dose levels of AXA1125.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2022
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AXA1665 is an EMM composition of 8 amino acids and derivatives that targets three key nodes: ammonia toxicity, amino acid imbalance, and muscle wasting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : AXA1125
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $25.0 million
Deal Type : Public Offering
Details : Axcella intends to use the net proceeds from the offering to complete its Long COVID Phase 2a clinical trial for AXA1125 and, assuming positive data for program; complete enrollment of its EMMPACT Phase 2b clinical trial in NASH; and EMMPOWER Phase 2 cli...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : AXA1125
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $25.0 million
Deal Type : Public Offering
Lead Product(s) : AXA1125
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
Details : AXA1125 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Post-Acute COVID-19 Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : AXA1125
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AXA1125
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
Details : In two prior successful clinical studies and in preclinical models, AXA1125 has demonstrated an ability to restore mitochondrial function and improve energetic efficiency via increased fatty acid oxidation, restored cellular homeostasis, and reduced infl...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : AXA1125
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AXA1665-002 was a placebo-controlled, randomized clinical study that investigated the safety, tolerability and physiological impact of AXA1665 in 60 subjects with mild (Child Pugh A) and moderate (Child Pugh B) hepatic insufficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Details : AXA1125 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : AXA1125
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
Details : AXA1665 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatic Encephalopathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2021